TABLE 2.
Passive protection from lethal sepsis
| Challenge strain |
Survival of controls (P0) (efficacy studies) |
P2-treated survival (efficacy studies) |
P-value Fisher’s exact test (two-tailed) |
Average serum IgG level in controlsa (ng/mL) |
Average serum IgG level in P2a (ng/mL) |
|---|---|---|---|---|---|
| KPO1 | 0/20 (0%) | 20/20 (100%) | <0.0001 | <15 | 160 |
| KPO2 | 0/20 (0%) | 18/20 (90%) | <0.0001 | <15 | 628 |
| KPO3 | 1/20 (5%) | 17/20 (85%) | <0.0001 | 19 | 415 |
| PA O4 | 2/20 (10%) | 19/20 (95%) | <0.0001 | <15 | 402 |
| PA O5 | 0/20 (0%) | 19/20 (95%) | <0.0001 | <15 | 195 |
| PA O6 | 1/20 (5%) | 18/20 (90%) | <0.0001 | <15 | 332 |
| PA O11 | 0/20 (0%) | 8/20 (40%) | 0.003 | <15 | 292 |
a
Collected at the time of infectious challenge (0 h) after 0.2 mL IP administration of antisera at −20 and −2 h. PA challenges at 3 × 107 CFU. KP O1 and KP O2 at 2 × 104 CFU and KP O3 at 1 × 105 CFU.